Your browser doesn't support javascript.
loading
Cyclodextrins as therapeutic drugs for treating lipid metabolism disorders.
Wu, Jiao; Li, Jingyi; Shao, Wenxiang; Hu, Yue; Chen, Hongfu; Chen, Yunhai; Chen, Yong; Liu, Qian; Ao, Meiying.
Afiliação
  • Wu J; Discipline of Chinese and Western Integrative Medicine, College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
  • Li J; Discipline of Chinese and Western Integrative Medicine, College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
  • Shao W; Discipline of Chinese and Western Integrative Medicine, College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
  • Hu Y; Discipline of Chinese and Western Integrative Medicine, College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
  • Chen H; Discipline of Chinese and Western Integrative Medicine, College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
  • Chen Y; Discipline of Chinese and Western Integrative Medicine, College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
  • Chen Y; Nanoscale Science and Technology Laboratory, Institute for Advanced Study, Nanchang University, Nanchang, Jiangxi, China.
  • Liu Q; Integrated Chinese and Western Medicine Institute for Children Health &Drug Innovation, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
  • Ao M; Discipline of Chinese and Western Integrative Medicine, College of Traditional Chinese Medicine, Jiangxi University of Chinese Medicine, Nanchang, Jiangxi, China.
Obes Rev ; 25(4): e13687, 2024 Apr.
Article em En | MEDLINE | ID: mdl-38204297
ABSTRACT

OBJECTIVE:

This study sought to systematically compare the efficacy and mechanism of cyclodextrins as drug interventions in lipid metabolism diseases, potentially providing ideas for subsequent research directions and clinical applications.

METHODS:

We used the bibliometric method for feature mining, applied VOSviewer software for clustering analysis, and applied content analysis for objective descriptions and accurate analysis.

RESULTS:

(1) We collected more than 50 studies, which is the basic database of this study. (2) The academic bubble map showed that this research area was popular in the United States. (3) Cluster analysis showed that the intensively studied diseases in this field were Niemann-Pick type C (NPC), atherosclerosis (AS), and obesity. The hot-spot cyclodextrin types were HP-ß-CD. (4) Literature measurement revealed the involvement of 15 types of lipid metabolism diseases. Among them, NPC, diabetes, and obesity were studied in clinical trials. Dyslipidemia and AS have been reported relatively more frequently in animal experiments. The studies of cellular experiments provide insight into the molecular mechanisms that intervene in lipid metabolism diseases from multiple perspectives. The exploration of the molecular mechanisms by which cyclodextrins exert their pharmacological effects mainly revolves around lipid metabolism.

CONCLUSION:

It is worthwhile to investigate the role and mechanism of cyclodextrins in other lipid metabolism diseases. The potential efficacy evaluation of cyclodextrins as pharmaceutical drugs for oral or injectable formulations is less studied and may become a new focus in the future.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ciclodextrinas / Transtornos do Metabolismo dos Lipídeos Limite: Animals Idioma: En Revista: Obes Rev Assunto da revista: METABOLISMO Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ciclodextrinas / Transtornos do Metabolismo dos Lipídeos Limite: Animals Idioma: En Revista: Obes Rev Assunto da revista: METABOLISMO Ano de publicação: 2024 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido